Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02807480 · ClinicalTrials.gov registry record · NA

Approach-Avoidance Conflict-a Multi-level Predictor for Therapy Response

A NA study of Generalized Anxiety Disorder, sponsored by Laureate Institute for Brain Research.

Completed
Registry status
NA
Development phase
121
Enrollment target
1
Study location

NCT02807480: Completed NA study of Generalized Anxiety Disorder, sponsored by Laureate Institute for Brain Research.

NCT02807480 is a NA study of Generalized Anxiety Disorder that has completed, run by Laureate Institute for Brain Research. The registered enrollment target is 121 participants, below the 212-participant average among 48 other Generalized Anxiety Disorder trials with a reported enrollment target (43% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02807480, a NA study of Generalized Anxiety Disorder, has completed, sponsored by Laureate Institute for Brain Research.

COMPLETED
Registry status
NA
Development phase
121 participants
Enrollment target
1
Study location

Study Summary

This project aims to identify brain and behavioral characteristics of individuals experiencing symptoms of generalized anxiety disorder that will predict the effectiveness of Exposure-based therapy versus Behavioral Activation Therapy. Brain imaging aspects of the study will use functional magnetic resonance imaging (fMRI) and electroencephalography (EEG). Behavioral assessments will include self-report questionnaires, computer-based and observational tasks, and interviews. Assessments will focus on how individuals process positive information (such as reward) and negative information (such as distressing images), as well as how people make decisions. These assessments will be conducted across 2-3 in-person sessions prior to beginning the treatment, and will be repeated across 2-3 in-person sessions after completing treatment. A blood draw will also be conducted pre- and post- treatment. Both the Exposure-based and Behavior Activation therapy will consist of 10, 90-minute weekly therapy sessions conducted in small groups.

Primary Outcome

Test the relationship between imaging and behavioral factors and the level of symptoms at baseline assessment. Scores on the Generalized Anxiety Disorder - 7 item scale (GAD-7) range from 0 to 21, higher scores reflect greater symptom severity.

Interventions

  • DEVICE Magnetic resonance imaging (MRI)
  • BEHAVIORAL Exposure-based therapy
  • BEHAVIORAL Surveys and Interviews
  • BEHAVIORAL Behavioral Activation therapy
  • BEHAVIORAL Computer-based behavioral assessment

Study Locations (1)

Oklahoma

  • Laureate Institute for Brain Research - Tulsa

Trial Details

FieldValue
Enrollment Target 121 participants
Start Date 2016-06
Est. Completion 2022-03-04
Phase NA

What the finished NCT02807480 record still lists

NCT02807480 is an interventional study that assigns participants to a tested intervention. The registered 121 participants enrollment target is mid-sized for trials with a published cap, below the 212-participant average among 48 other Generalized Anxiety Disorder trials with a reported enrollment target (43% lower).

The record links to 1 condition, with Generalized Anxiety Disorder appearing as the primary indexed condition, and to 5 interventions - of which Magnetic resonance imaging (MRI) is the first listed.

NCT02807480 reports a single indexed study location in Oklahoma.

Frequently Asked Questions

What is clinical trial NCT02807480 about?

NCT02807480 is a clinical study titled "Approach-Avoidance Conflict-a Multi-level Predictor for Therapy Response". This project aims to identify brain and behavioral characteristics of individuals experiencing symptoms of generalized anxiety disorder that will predict the effectiveness of Exposure-based therapy versus Behavioral Activation Therapy. Brain imaging aspects of the study will use functional magnetic ...

What is the current status of trial NCT02807480?

This trial is currently completed. It is a NA study. The enrollment target is 121 participants. The study started on 2016-06. Estimated completion is 2022-03-04.

What conditions does trial NCT02807480 study?

This clinical trial studies the following conditions: Generalized Anxiety Disorder.

What interventions are being tested in trial NCT02807480?

The interventions under investigation include: Magnetic resonance imaging (MRI) (DEVICE), Exposure-based therapy (BEHAVIORAL), Surveys and Interviews (BEHAVIORAL), Behavioral Activation therapy (BEHAVIORAL), Computer-based behavioral assessment (BEHAVIORAL).

Who is sponsoring clinical trial NCT02807480?

This trial is sponsored by Laureate Institute for Brain Research, which has 45 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02807480 being conducted?

This trial has 1 study location across Oklahoma. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Generalized Anxiety Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02807480's enrollment target sits among peer trials

121 26th of 48 higher than 23 of 48 other Generalized Anxiety Disorder trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Generalized Anxiety Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03476681 · 121 participants · Phase 1

    Study of NEO-201 in Solid Tumors Expansion Cohorts

  • NCT04655118 · 121 participants · Phase 2

    Study of TL-895 in Subjects With Myelofibrosis or Indolent Systemic Mastocytosis

  • NCT04676802 · 121 participants · Phase 2

    Pain Relief After Trapeziectomy: Ibuprofen & Acetaminophen Versus Oxycodone

  • NCT05169515 · 121 participants · Phase 1

    A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02807480, the US trial registry maintained by the National Library of Medicine. NCT02807480 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.